Kristy Wood is currently Director of Non-Viral Delivery at Intellia Therapeutics and is responsible for over-seeing delivery technologies for therapeutic applications of CRISPR/Cas9. Kristy has more than 10 years of industrial experience in developing novel drug delivery systems for the delivery of nucleic acids and proteins. Her interest in nucleic acid delivery began as a scientist at Baxter Healthcare and has led her to work on projects to deliver ASO, siRNA, and mRNA through various routes of administration across many therapeutic areas. Kristy has been involved in small-scale formulations, scaling-up processes, and completing tech transfers moving drug product formulations from research into development. Previously, she was focused on the manufacturing and delivery of mRNA as a therapeutic for protein replacement using lipid nanoparticle delivery systems at both Pfizer and Shire. Kristy has been issued a number of U.S. patents in the mRNA field. She received her Ph.D. in Biomedical Engineering from the University of Texas at Austin working with Professor Nicholas Peppas and her B.S. in Biomedical Engineering from the University of Wisconsin-Madison.